EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer

Yu Zhao iD, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao

Technology in Cancer Research & Treatment · 2023

DOI: 10.1177/15330338231202307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Yu Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Haihe Laboratory of Cell Ecosystem Innovation Fund, Tianjin Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Immune checkpoint (ICP) expression in tumor cells could directly or indirectly affect the results of immunotherapy. ICP ligands on tumor cells usually bind their immune cell receptors to inhibit the activity, resulting in tumor immune escape. Thus, the purpose of this study was to ascertain the impact of various chemotherapeutic drugs on ICP expression in non-small cell lung cancer (NSCLC) cell lines with different pathological subtypes to provide a basis for the development of a superior regimen of chemotherapy combined with ICP blockade.

Methods

Several first-line chemotherapy agents (cisplatin, carboplatin, paclitaxel, gemcitabine, vinorelbine, and pemetrexed) were selected to treat different NSCLC cell lines (squamous carcinoma H1703, adenocarcinoma A549, and large cell cancer H460) for 72 hours, and then the changes in ICP expression in the tumor cells were observed through flow cytometry.

Results

Cisplatin, carboplatin, and paclitaxel upregulated the expressions of programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2) in A549 and H460 cell lines. Meanwhile, vinorelbine and pemetrexed upregulated PD-L1 and PD-L2 in H1703, A549, and H460 cell lines. Paclitaxel, gemcitabine, vinorelbine, and pemetrexed significantly upregulated the expressions of both galectin-9 and high-mobility group box protein 1 (HMGB1) in the A549 cell line. Cisplatin and paclitaxel significantly upregulated the expressions of major histocompatibility complex-II (MHC-II), galectin-3, α-synuclein, and fibrinogen-like protein 1 (FGL1) in A549 and H460 cell lines. In addition, cisplatin and vinorelbine significantly upregulated the expressions of both CD155 and CD112 in the H460 cell line. Vinorelbine upregulated MHC-I in all three cell lines.

Conclusion

Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansCisplatinVinorelbineCarboplatinPemetrexedB7-H1 AntigenLigandsDeoxycytidineGemcitabinePaclitaxelAntineoplastic Combined Chemotherapy ProtocolsFibrinogen

Stichwörter der Autor:innen

NSCLCchemotherapycombination therapyimmune checkpointimmunotherapy

Substanzen

CisplatinVinorelbineCarboplatinPemetrexedB7-H1 AntigenLigandsDeoxycytidineAntineoplastic AgentsGemcitabinePaclitaxel

Autor:innen und Institutionen

  • Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
  • Haihe Laboratory of Cell Ecosystem, Tianjin, China.
  • Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

ORCID-Profile: Yu Zhao

Förderung

  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • Tianjin Natural Science Foundation

Zitieren

APA

Zhao, Y., Wang, Z., Shi, X., Liu, T., Yu, W., Ren, X., & Zhao, H. (2023). Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231202307

Vancouver

Zhao Y, Wang Z, Shi X, Liu T, Yu W, Ren X, et al. Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231202307

BibTeX
@article{Zhao2023,
  author = {Zhao, Yu and Wang, Zhe and Shi, Xiuhuan and Liu, Ting and Yu, Wenwen and Ren, Xiubao and Zhao, Hua},
  title = {Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer},
  journal = {Technology in Cancer Research & Treatment},
  year = {2023},
  doi = {10.1177/15330338231202307}
}
Kostenlos starten →